A Phase 4 interventional study of Oxytocin nasal spray and Social Cognition Skills Training in Schizophrenia, sponsored by University of California, Los Angeles. Completed at 1 site in United States. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-03.
Sponsored by University of California, Los Angeles · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 31 studies testing oxytocin in Schizophrenia — none open to participants now, 1 under way, none of them phase 3. Oxytocin · Schizophrenia.
Among the 31 studies testing oxytocin in Schizophrenia, this one is the 11th largest by enrollment, is one of 2 that started in 2018, is one of 2 in phase 4, and was the 25th registered.
3,574 studies on the registry are indexed under Schizophrenia; 494 are open to participants now.
Browse Schizophrenia studies →None of the 31 studies testing oxytocin in Schizophrenia is open now. The open studies under Schizophrenia, anywhere →
Oxytocin: first FDA approval 1980 (SYNTOCINON). What it is approved for, and how studies give it, is on its page →
Of the 333 Schizophrenia studies recruiting now, 63 (19%) set no upper age limit and 258 (77%) stop at 75 or younger; 42 take children under 18; 83 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
31 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 9 · Phase 4 2
First in 2008; this study’s year is marked. 2 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 59 is below the median of 70 across 2,952 interventional studies indexed under Schizophrenia.
Median enrollment 43 across the 31 interventional studies. Of the 27 that completed or were terminated, 14 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 31 has an industry lead sponsor. The 10 most frequent:
University of California, Los Angeles is the lead sponsor of 1,172 studies on the registry; 195 are open to participants now.
Of its 95 completed or terminated interventional studies of FDA-regulated products, 70 (74%) have results posted.
27 studies in Schizophrenia by University of California, Los Angeles: 3 open now, 3 under way, none of them phase 3. Of 22 finished, 11 (50%) have results posted.
Among the 27 studies in Schizophrenia by University of California, Los Angeles, this one is the 16th largest by enrollment, is the only one that started in 2018, is one of 10 in phase 4, and was the 22nd registered.
University of California, Los Angeles’s Schizophrenia studies by the year they started, since 1999.
None of the studies under way reaches primary completion within a year.
Among the 31 studies testing oxytocin in Schizophrenia, from their registry updates:
Among University of California, Los Angeles’s 27 in Schizophrenia:
This tab as a report to print or save as PDF → With an account.
This study will measure whether the engagement of intranasal oxytocin with a brain target is related to effects on learning during a social cognition training program.
The study will determine whether oxytocin (OT) administration 30 min before a training session enhances the learning of social information in the context of a social cognitive skills training (SCST) program, and it will test a possible mediator of this effect. Subjects with psychotic disorders will be randomized to one of four groups in a 2 by 2 factorial design: OT with SCST; Placebo with SCST; OT with training control condition; placebo with training control condition. Target engagement will be measured in an OT challenge (placebo versus OT one week apart) prior to baseline assessment. The measure of target engagement will be EEG mu suppression while observing biological motion. A social cognition battery will be administered at baseline, at midpoint after 6 weeks of SCST, and at completion of training at 12 weeks. The battery will include measures of social cue identification and mentalizing.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Oxytocin with SCST (active condition)
Drug: Oxytocin nasal spray · Behavioral: Social Cognition Skills Training
Administration of OT with control psychosocial treatment
Drug: Oxytocin nasal spray · Behavioral: Health Management
Administration of Placebo with active psychosocial treatment
Behavioral: Social Cognition Skills Training · Drug: Placebo nasal spray
Administration of Placebo with control psychosocial treatment
Behavioral: Health Management · Drug: Placebo nasal spray
nasal spray
Also known as: OT
Group based training in social cognition skills
Also known as: SCST
Group-based training in mental health management
Also known as: HM
placebo condition
Also known as: PBO
Social Cue Identification
Social cue identification is a composite score created for this study of the Emotion Identification Test from the Ekman Program (Ekman) and the Profile of Nonverbal Sensitivity (PONS). People use information from identifying emotions on faces and other nonverbal cues to assess an individual's ability to identify social cues. The primary summary measure for each test (Ekman, PONS) is mean-centered and standardized to create a Z-score. The two Z-scores are then averaged to create Social Cue Identification. A Z-score standardizes data to a scale (a z-distribution with a mean of 0 and standard deviation of 1). Higher scores represent a better outcome. Ekman, P., Subtle Expression Training Tool (SETT) \& Micro Expression Training Tool (METT), 2004, Paul Ekman www.paulekman.com. Rosenthal R, Hall J, DiMatteo M, Rogers P, Archer D. Profile of nonverbal sensitivity (PONS test): Manual. Unpublished manuscript available from JA Hall, Northeastern University, Boston, MA 2011.
Time frame: 16 weeks
Social Cognition: Mentalizing
Mentalizing is a composite measure of higher-order social cognition that assesses an individual's ability to understand the thoughts, intentions, beliefs, and experiences of others. The composite combines scores from The Awareness of Social Inference Test (TASIT) and the Empathic Accuracy Task. TASIT assesses the ability to infer others' intentions and beliefs from social interactions, and the Empathic Accuracy Task assesses the ability to accurately infer another person's emotional experiences. Raw scores from each measure were standardized to Z-scores and averaged to create the Mentalizing composite score: Mentalizing = mean(TASIT Total Z-score, Empathic Accuracy Z-score). A Z-score of 0 represents the sample mean. Positive Z-scores indicate better-than-average mentalizing ability, negative Z-scores indicate worse-than-average mentalizing ability. Higher Z-scores represent better performance. There are no established clinical thresholds for interpretation of this composite measure
Time frame: 16 weeks
Non-Social Cognition
The secondary outcome measure of Non-social cognition is based on the MATRICS Consensus Cognitive Battery (MCCB). The MCCB overall score is a composite score from the MATRICS that provides a standardized measure of an individual's global cognitive function, with a mean (SD) of 50(10) for a healthy control group. Higher scores indicate better cognitive function. The score is interpreted based on a T-score scale that accounts for age and sex.
Time frame: 16 weeks
To meet our recruitment goals, patients with schizophrenia will be recruited from five sources: previous participants who have asked to be contacted for future studies by initialing this preference in a consent form from another study, participants of the MIRECC Treatment and Clinical Neuroscience Repository (Marder #0042), outpatient mental health clinics within the VA Greater Los Angeles Healthcare System (VAGLAHS), the UCLA Psychosis Clinic; and local board and care facilities.
| Milestone | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM |
|---|---|---|---|---|
| Started | 16 | 13 | 12 | 18 |
| Completed | 16 | 11 | 11 | 18 |
| Not completed | 0 | 2 | 1 | 0 |
| Withdrew: Subject tested positive on urine drug screen for methanphetamine | 0 | 1 | 0 | 0 |
| Withdrew: Withdrew before baseline due to work/relocation | 0 | 1 | 1 | 0 |
| Milestone | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM |
|---|---|---|---|---|
| Started | 16 | 11 | 11 | 18 |
| Completed | 15 | 11 | 9 | 14 |
| Not completed | 1 | 0 | 2 | 4 |
| Withdrew: Lost to follow-up | 1 | 0 | 0 | 1 |
| Withdrew: Death | 0 | 0 | 1 | 0 |
| Withdrew: Adverse event | 0 | 0 | 1 | 1 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 2 |
| Milestone | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM |
|---|---|---|---|---|
| Started | 15 | 11 | 9 | 14 |
| Completed | 14 | 11 | 9 | 14 |
| Not completed | 1 | 0 | 0 | 0 |
The secondary outcome measure of Non-social cognition is based on the MATRICS Consensus Cognitive Battery (MCCB). The MCCB overall score is a composite score from the MATRICS that provides a standardized measure of an individual's global cognitive function, with a mean (SD) of 50(10) for a healthy control group. Higher scores indicate better cognitive function. The score is interpreted based on a T-score scale that accounts for age and sex.
| Standard Deviations | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM |
|---|---|---|---|---|
| Non-Social Cognition | 38.2 ± 3.2 | 40.1 ± 3.9 | 40.9 ± 4.0 | 37.5 ± 3.2 |
Social cue identification is a composite score created for this study of the Emotion Identification Test from the Ekman Program (Ekman) and the Profile of Nonverbal Sensitivity (PONS). People use information from identifying emotions on faces and other nonverbal cues to assess an individual's ability to identify social cues. The primary summary measure for each test (Ekman, PONS) is mean-centered and standardized to create a Z-score. The two Z-scores are then averaged to create Social Cue Identification. A Z-score standardizes data to a scale (a z-distribution with a mean of 0 and standard deviation of 1). Higher scores represent a better outcome. Ekman, P., Subtle Expression Training Tool (SETT) \& Micro Expression Training Tool (METT), 2004, Paul Ekman www.paulekman.com. Rosenthal R, Hall J, DiMatteo M, Rogers P, Archer D. Profile of nonverbal sensitivity (PONS test): Manual. Unpublished manuscript available from JA Hall, Northeastern University, Boston, MA 2011.
| Z-Score | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM |
|---|---|---|---|---|
| Week12 Endof Treatment | 0.13 ± 0.2 | 0.05 ± 0.2 | 0.86 ± 0.2 | 0.23 ± 0.2 |
| Week 0 Start of Treatment | -.23 ± .22 | 0.0045 ± 0.26 | 0.65 ± 0.26 | 0.067 ± 0.21 |
Mentalizing is a composite measure of higher-order social cognition that assesses an individual's ability to understand the thoughts, intentions, beliefs, and experiences of others. The composite combines scores from The Awareness of Social Inference Test (TASIT) and the Empathic Accuracy Task. TASIT assesses the ability to infer others' intentions and beliefs from social interactions, and the Empathic Accuracy Task assesses the ability to accurately infer another person's emotional experiences. Raw scores from each measure were standardized to Z-scores and averaged to create the Mentalizing composite score: Mentalizing = mean(TASIT Total Z-score, Empathic Accuracy Z-score). A Z-score of 0 represents the sample mean. Positive Z-scores indicate better-than-average mentalizing ability, negative Z-scores indicate worse-than-average mentalizing ability. Higher Z-scores represent better performance. There are no established clinical thresholds for interpretation of this composite measure
| points on a scale | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM |
|---|---|---|---|---|
| Week 12 End of Treatment | 0.0031 ± 0.21 | 0.19 ± 0.25 | -.026 ± 0.26 | 0.09 ± 0.21 |
| Week 0 Start of Treatment | -0.1199 ± 0.2099 | 0.08177 ± 0.253 | 0.3165 ± 0.2531 | -.0772 ± .1985 |
Collected over Adverse Events Collected from enrollment to end of trial (12 weeks). Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| OT/SCST | 0/16 (0%) | 0/16 (0%) | 5/16 (31.3%) |
| OT/HM | 0/13 (0%) | 0/13 (0%) | 4/13 (30.8%) |
| Pbo/SCST | 1/12 (8.3%) | 1/12 (8.3%) | 5/12 (41.7%) |
| Pbo/HM | 0/18 (0%) | 0/18 (0%) | 8/18 (44.4%) |
| Event | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM |
|---|---|---|---|---|
| POSITIVE COVID-19Investigations | 0/16 | 0/13 | 1/12 | 0/18 |
| Event | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM |
|---|---|---|---|---|
| ANXIETYPsychiatric disorders | 0/16 | 0/13 | 1/12 | 0/18 |
| EPIPHORAEye disorders | 0/16 | 0/13 | 1/12 | 0/18 |
| HEADACHENervous system disorders | 0/16 | 0/13 | 1/12 | 0/18 |
| INSOMNIAPsychiatric disorders | 0/16 | 0/13 | 1/12 | 0/18 |
| RUNNY NOSERespiratory, thoracic and mediastinal disorders | 0/16 | 0/13 | 1/12 | 0/18 |
| COMMON COLDInfections and infestations | 0/16 | 1/13 | 0/12 | 0/18 |
| GERDGastrointestinal disorders | 0/16 | 1/13 | 0/12 | 0/18 |
| POSITIVE COVID-19Investigations | 1/16 | 1/13 | 0/12 | 1/18 |
| TOOTH INFECTIONInfections and infestations | 0/16 | 1/13 | 0/12 | 0/18 |
| BACK PAINMusculoskeletal and connective tissue disorders | 1/16 | 0/13 | 0/12 | 0/18 |
| Age, Continuous(years) | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM | Total |
|---|---|---|---|---|---|
| Mean | 42.7 ± 11.9 | 51.6 ± 8.7 | 47.8 ± 11.6 | 42.1 ± 12.7 | 45.2 ± 11.9 |
| Sex: Female, Male(Participants) | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM | Total |
|---|---|---|---|---|---|
| Female | 2 | 3 | 2 | 6 | 13 |
| Male | 14 | 8 | 9 | 12 | 43 |
| Race (NIH/OMB)(Participants) | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 | 4 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 10 | 7 | 6 | 9 | 32 |
| White | 6 | 3 | 4 | 5 | 18 |
| More than one race | 0 | 1 | 1 | 0 | 2 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Ethnicity (NIH/OMB)(Participants) | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 1 | 1 | 3 | 1 | 6 |
| Not Hispanic or Latino | 15 | 10 | 8 | 17 | 50 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Emotion Identification Test from Ekman Program.(points on a scale) | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM | Total |
|---|---|---|---|---|---|
| Mean | 42.1 ± 7.4 | 43.3 ± 3.7 | 49.3 ± 6.7 | 43.8 ± 6.9 | 44.18 ± 6.8 |
| Profile of Nonverbal Sensitivity(points on a scale.) | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM | Total |
|---|---|---|---|---|---|
| Mean | 75.6 ± 8.1 | 79.8 ± 6.5 | 81.4 ± 6.2 | 79.8 ± 5.3 | 78.9 ± 6.8 |
| The Awareness of Social Inference Test (TASIT).(Percent) | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM | Total |
|---|---|---|---|---|---|
| Mean | 46.6 ± 8.6 | 47.1 ± 7.9 | 49 ± 8.3 | 46.2 ± 8.1 | 47.0 ± 8.1 |
| The Empathic Accuracy Task.(Correlation coefficient) | OT/SCST | OT/HM | Pbo/SCST | Pbo/HM | Total |
|---|---|---|---|---|---|
| Mean | 0.6 ± 0.2 | 0.6 ± 0.1 | 0.6 ± 0.2 | 0.6 ± 0.1 | 0.6 ± 0.1 |
2 further baseline measures are reported on the registry.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Individual participant data from this study have been submitted to the National Data Archive https://nda.nih.gov/ under collection number C2305. Researchers may request access via the website. Item level data from study measures are available to researchers. A complete list of data available can be found on the NDA website.
Time frame: Data are already shared under Collection id C2305 via the National Data Archive https://nda.nih.gov/. Further information can be found on the website or by emailing NDAHelp@mail.nih.gov.
Access criteria: Information on data access can be found here: https://nda.nih.gov/user/dashboard/data_permissions
Data sharing details ↗ · nda.nih.gov
Ran from Jan 2018 to primary completion in Jul 2024, 78 months.
Results were first posted in Nov 2026, 2 years 3 months after primary completion.
Of 71 non-industry phase 4 interventional studies under Schizophrenia, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 27 and three quarters within 64. This study's 78 months is above that.
Counting every sponsor, half of 88 studies reached it within 39 months; a quarter within 20 and three quarters within 63.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Oxytocin
University of California, Los Angeles →